Evidence map›Paper›PMID 28337142›Full record

ArticleFrontiers in pharmacology2017

Icariside II Effectively Reduces Spatial Learning and Memory Impairments in Alzheimer's Disease Model Mice Targeting Beta-Amyloid Production.

Lingli Yan, Yuanyuan Deng, Jianmei Gao, Yuangui Liu, Fei Li, Jingshan Shi, Qihai Gong

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
5.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. CZYH AlleviatesBehavioural neurology · 2019
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Lingli YanDepartment of Pharmacology and Key Laboratory of Basic Pharmacology of Ministry of Education, Zunyi Medical University Zunyi, China.
Yuanyuan DengDepartment of Pharmacology and Key Laboratory of Basic Pharmacology of Ministry of Education, Zunyi Medical University Zunyi, China.
Jianmei GaoDepartment of Pharmacy, Zunyi Medical University Zunyi, China.
Yuangui LiuDepartment of Pharmacology and Key Laboratory of Basic Pharmacology of Ministry of Education, Zunyi Medical University Zunyi, China.
Fei LiDepartment of Pharmacology and Key Laboratory of Basic Pharmacology of Ministry of Education, Zunyi Medical University Zunyi, China.
Jingshan ShiDepartment of Pharmacology and Key Laboratory of Basic Pharmacology of Ministry of Education, Zunyi Medical University Zunyi, China.
Qihai GongDepartment of Pharmacology and Key Laboratory of Basic Pharmacology of Ministry of Education, Zunyi Medical University Zunyi, China.
Zunyi Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Icariside II (ICS II) is a broad-spectrum anti-cancer natural compound extracted from

Indexed as

a disintegrin and metalloproteinase domain 10Alzheimer’s diseasebeta-amyloidbeta-site APP cleavage enzyme 1icariside IIperoxisome proliferator-activated receptor-γ

Identifiers

PMID28337142
PMCPMC5340752
OpenAlexW2592190558

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.